Author:
Adly Mina E.,Gedawy Ehab M.,El-Malah Afaf A.,Khalil Omneya M.
Abstract
AbstractOur main goal was to design and synthesize novel lomefloxacin derivatives that inhibit the topoisomerase II enzyme, leading to potent anticancer activity. Lomefloxacin derivatives substituted at position 3 and 7 were synthesized and screened for cytotoxic activity utilizing 60 different human cancer cell lines. Furthermore, compounds 3a,b,c,e that revealed potent broad-spectrum anticancer activity (with mean percent GI more than 47%) were further evaluated using five dose concentrations and calculating the GI50. Compound 3e was then evaluated for cell cycle analysis and demonstrated cell cycle arrest at the G2-M phase. Moreover, the mechanism of action was determined by determining the topoisomerase inhibitory activity and the molecular modeling study. Compounds 3a,b,c,e showed broad spectrum anticancer activity. Lomefloxacin derivative 5f showed selective cytotoxic activity against melanoma SK-MEL-5 cell line. Compound 3e demonstrated comparable topoisomerase II inhibition to doxorubicin with IC50 of 0.98 µM.
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Chu, D. T. & Fernandes, P. B. Structure–activity relationships of the fluoroquinolones. Antimicrob. Agents Chemother. 33, 131 (1989).
2. Robinson, M. J. et al. Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage. J. Biol. Chem. 266, 14585–14592 (1991).
3. Yamashita, Y., Ashizawa, T., Morimoto, M., Hosomi, J. & Nakano, H. Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity. Cancer Res. 52, 2818–2822 (1992).
4. Bisacchi, G. S. & Hale, M. R. A ‘double-edged’ scaffold: Antitumor power within the antibacterial quinolone. Curr. Med. Chem. 23, 520–577 (2016).
5. Radl, S. & Daxt, S. Quinolone congeners as mammalian topoisomerase-ll inhibitors. Curr. Med. Chem. 1, 262 (1994).